Online citations, reference lists, and bibliographies.
← Back to Search

Impact Of Age At Diagnosis On Prostate Cancer Treatment And Survival.

Seth K. Bechis, P. Carroll, Matthew R. Cooperberg
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE Older men are more likely to be diagnosed with high-risk prostate cancer and to have lower overall survival. As a result, age often plays a role in treatment choice. However, the relationships among age, disease risk, and prostate cancer-specific survival have not been well established. PATIENTS AND METHODS We studied men in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database with complete risk, treatment, and follow-up information. High-risk patients were identified by using the validated Cancer of the Prostate Risk Assessment (CAPRA) score. Competing risks regression was used to identify the independent impact of age on cancer-specific survival. We also analyzed the effect of local treatment on survival among older men with high-risk disease. RESULTS In all, 26% of men age ≥ 75 years presented with high-risk disease (CAPRA score 6 to 10). Treatment varied markedly with age across risk strata; older men were more likely to receive androgen deprivation monotherapy. Controlling for treatment modality alone, or for treatment and risk, age did not independently predict cancer-specific survival. Furthermore, controlling for age, comorbidity, and risk, older men with high-risk tumors receiving local therapy had a 46% reduction in mortality compared with those treated conservatively. CONCLUSION Older patients are more likely to have high-risk prostate cancer at diagnosis and less likely to receive local therapy. Indeed, underuse of potentially curative local therapy among older men with high-risk disease may in part explain observed differences in cancer-specific survival across age strata. These findings support making decisions regarding treatment on the basis of disease risk and life expectancy rather than on chronologic age.
This paper references
10.1016/S0090-4295(03)00690-3
Continued undertreatment of older men with localized prostate cancer.
K. Schwartz (2003)
10.1093/JNCI/DJI313
30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity.
S. Alibhai (2005)
10.1111/j.1464-410X.2007.07487.x
Management of localized prostate cancer in senior adults: the crucial role of comorbidity
J. Fitzpatrick (2008)
10.1016/S0022-5347(05)00647-6
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE.
Paige L Marr (2006)
10.1200/JCO.2009.26.0133
Time trends and local variation in primary treatment of localized prostate cancer.
M. Cooperberg (2010)
10.1093/JNCI/DJJ230
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
V. Shahinian (2006)
10.1016/j.juro.2008.01.044
Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE.
B. Konety (2008)
10.1001/jama.2009.1348
Outcomes of localized prostate cancer following conservative management.
G. Lu-Yao (2009)
Adverse events associated with hormonal therapy for prostate cancer.
R. Kumar (2005)
10.1080/01621459.1999.10474144
A Proportional Hazards Model for the Subdistribution of a Competing Risk
J. Fine (1999)
Prostate cancer in elderly men.
A. Stangelberger (2008)
10.7326/0003-4819-157-2-201207170-00459
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
V. Moyer (2012)
10.1016/S0022-5347(05)67643-4
Differences between urologists in the United States and Canada in the approach to prostate cancer.
N. Fleshner (2000)
10.1016/j.urolonc.2009.07.015
Prostate cancer in the elderly.
H. Heinzer (2009)
10.1056/NEJMoa0810696
Mortality results from a randomized prostate-cancer screening trial.
G. Andriole (2009)
10.1016/S0022-5347(01)62152-9
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.
M. Kattan (1998)
10.1056/NEJM199511023331824
Survival after the age of 80 in the United States, Sweden, France, England, and Japan.
K. Manton (1995)
10.1111/j.1464-410X.2007.07410.x
Radical prostatectomy in men aged ≥70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram
L. Richstone (2008)
10.1111/j.1464-410X.2009.08718.x
Robot‐assisted radical prostatectomy in men aged ≥70 years
K. Greco (2009)
10.1016/J.UROLOGY.2003.10.013
Epidemiology of prostate cancer.
E. Crawford (2003)
10.1016/S0022-5347(01)66718-1
Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association.
R. Middleton (1995)
Deaths: preliminary data for 2011.
D. Hoyert (2012)
10.1200/JCO.2003.09.034
Do older men benefit from curative therapy of localized prostate cancer?
S. Alibhai (2003)
10.1002/cncr.25456
Comparative risk‐adjusted mortality outcomes after primary surgery, radiotherapy, or androgen‐deprivation therapy for localized prostate cancer
M. Cooperberg (2010)
10.1016/S0090-4295(96)00226-9
The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor.
D. Lubeck (1996)
10.1016/S0090-4295(01)01434-0
Treatments for prostate cancer in older men: 1984-1997.
T. Bubolz (2001)
10.1016/s0084-4071(08)70151-9
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
A. Kibel (2007)
10.3322/caac.20073
Cancer Statistics, 2010
A. Jemal (2010)
10.7326/0003-4819-150-3-200902030-00020
Are Age-Based Criteria the Best Way to Determine Eligibility for Prostate Cancer Screening?
Ned Calonge (2009)
10.1111/j.1532-5415.2008.02091.x
Cause of Death in Older Men After the Diagnosis of Prostate Cancer
Melanie Ketchandji (2009)
10.1200/JCO.2005.06.742
Analysis of treatment practices for elderly cancer patients in Ontario, Canada.
C. Townsley (2005)
10.1200/JCO.2004.10.062
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.
M. Cooperberg (2004)
10.1001/archinternmed.2010.1
Physician visits prior to treatment for clinically localized prostate cancer.
T. Jang (2010)
10.1093/jnci/djp122
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
M. Cooperberg (2009)
10.1111/j.1464-410X.2007.07130.x
Clinicians are poor raters of life‐expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer
Jochen Walz (2007)
Deaths: preliminary data for 2000.
A. Miniño (2001)
10.7326/0003-4819-150-3-200902030-00018
Are age-based criteria the best way to determine eligibility for prostate cancer screening?
B. Konety (2009)
10.1097/01.JU.0000107247.81471.06
The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
M. Cooperberg (2004)
10.1002/CNCR.25914
Erratum: Comparative risk‐adjusted mortality outcomes after primary surgery, radiotherapy, or androgen‐deprivation therapy for localized prostate cancer
Matthew R. Cooperberg (2011)
Comparative risk-adjusted mortality outcomes following primary surgery , radiation therapy , or androgen deprivation therapy for localized prostate cancer
M. Cooperberg (2011)
10.1002/cncr.26392
Prostate cancer in the elderly
E. Scosyrev (2012)
10.1016/S0084-3873(08)79196-X
PSA Screening Among Elderly Men With Limited Life Expectancies
P. Loehrer (2008)
10.1111/j.1464-410X.2008.07614.x
Accuracy of life tables in predicting overall survival in patients after radical prostatectomy
Jochen Walz (2008)
10.1016/S0084-4071(09)79274-7
Screening and Prostate-Cancer Mortality in a Randomized European Study
A. Kibel (2009)
10.1002/(SICI)1097-0142(20000301)88:5<1122::AID-CNCR24>3.0.CO;2-Q
Primary treatment choices for men with clinically localized prostate carcinoma detected by screening
Y. Yan (2000)



This paper is referenced by
10.1038/pcan.2015.3
Nationally-representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America Project
K. Cary (2015)
10.1590/S1677-5538.IBJU.2017.03.04
PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Opinion: No
J. Clavell-Hernández (2017)
10.1016/J.PUROL.2016.07.002
Cancer de prostate des sujets âgés : place et rôle de l’évaluation gériatrique
Benoîte Méry (2016)
10.1038/pcan.2016.64
Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease
J. Tosoian (2017)
10.1016/j.clml.2020.06.005
Risk Factors for Cancer-specific Mortality and Cardiovascular Mortality in Patients With Diffuse Large B-cell Lymphoma.
J. Zhao (2020)
10.1200/JCO.2015.62.4650
Reply to G. Gandaglia et al and K. Lu.
D. Shumway (2015)
10.1016/j.juro.2016.01.122
Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with Prostate Cancer Treated with Radical Prostatectomy.
K. Boehm (2016)
Late-Stage Prostate Cancer and Prostate Cancer Mortality : A Population-Based Study
Sven Löffeler (2019)
10.1016/j.eururo.2014.09.008
Progress in management of low-risk prostate cancer: how registries may change the world.
M. Cooperberg (2015)
10.1111/j.1464-410X.2011.10927.x
Patients aged more than 70 had higher risk of locally advanced prostate cancers and biochemical recurrence in Korea
J. Kim (2012)
NCCN Guidelines Version 2 . 2015 Table of Contents Prostate Cancer Early Detection
Peter R. Carroll (2015)
Epidemiology of prostate cancer: current status.
Z-Q Tao (2015)
Determining the Natural History of Men with Initially Negative Prostate Biopsies
R. Sayyid (2017)
10.1016/j.radonc.2013.03.030
Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death.
Zumin Shi (2013)
10.1016/j.jgo.2018.09.006
Experience with age discrimination and attitudes toward ageism in older patients with cancer and their caregivers: A nationwide Korean survey.
D. Shin (2019)
10.1111/iju.13530
Impact of age on quality of life in patients with localized prostate cancer treated with high‐dose rate brachytherapy combined with external beam radiotherapy
K. Kikkawa (2018)
10.1016/j.sxmr.2017.09.003
Orgasmic Dysfunction Following Radical Prostatectomy: Review of Current Literature.
J. Clavell-Hernández (2018)
10.1007/s10552-020-01273-5
The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages
S. Knipper (2020)
10.1007/978-1-4471-2864-9_49
Radical Treatment for Localized Disease: An Overview of Options and Strategies for Decision Making
J. A. Smith (2013)
10.1001/jama.2015.6036
Trends in Management for Patients With Localized Prostate Cancer, 1990-2013.
M. Cooperberg (2015)
10.1371/journal.pone.0184160
Hepatocellular carcinoma in elderly: Clinical characteristics, treatments and outcomes compared with younger adults
Hui Guo (2017)
10.1016/j.semradonc.2012.05.005
Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity.
K. Hoffman (2012)
10.1007/978-1-61779-912-9_2
Patient Selection for Active Surveillance
J. Eifler (2012)
Title Sixth joint meeting of J-Cap and CaPSURE-A multinational perspective on prostate cancer management and patient outcomes Permalink
H. Akaza (2013)
10.1200/JCO.2016.68.0058
Active Surveillance in Younger Men With Prostate Cancer.
M. Leapman (2017)
10.1007/978-3-319-32700-6_34-1
Prostate Gland and Related Disorders
N. Nagaratnam (2017)
10.1016/J.JHEALECO.2019.102228
Medical innovation, education, and labor market outcomes of cancer patients.
Sung-hee Jeon (2019)
10.1097/COC.0000000000000589
Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients
F. Asamoah (2019)
10.1007/s00120-015-0025-x
Aktive Überwachung beim Niedrig-Risiko-Prostatakarzinom
A. Herlemann (2015)
Aging Men and Prostate Cancer
J. Reproduktionsmed (2018)
10.6004/JNCCN.2015.0181
Prostate Cancer Early Detection, Version 2.2015
P. Carroll (2015)
10.1001/jama.2015.6239
Discordant Interpretations of Breast Biopsy Specimens by Pathologists--Reply.
J. Elmore (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar